Christopher Hourigan DM, DPhil, FRCP

Christopher S. Hourigan, D.M., D.Phil., FACP, FRCP, is the director of the Virginia Tech FBRI Cancer Research Center in Washington D.C.. He is a board-certified hematologist oncologist trained at Oxford and then Johns Hopkins, and was recruited to the NIH in 2012 where he served as a tenured senior investigator and chief of the Laboratory of Myeloid Malignancies of the National Heart, Lung, and Blood Institute. The central focus of his translational research laboratory is precision oncology and “measurable residual disease” (MRD) in the rare, highly fatal blood cancer called acute myeloid leukemia (AML).

In July 2019 he was awarded the Presidential Early Career Award for Scientists and Engineers, the “highest honor bestowed by the United States Government to outstanding scientists and engineers who are beginning their independent research careers and who show exceptional promise for leadership in science and technology.” Dr. Hourigan is co-chair for genomics for the ELN International Consensus Committee on MRD in AML, co-chair of the Acute Leukemia Working Committee of the CIBMTR, co-PI of the FNIH Biomarkers Consortium for AML MRD (a NIH–FDA–Academic–industry partnership), and chair of the new national multicenter MEASURE protocol.

Dr. Hourigan is the recipient of many awards including the Presidential Early Career Awards for Scientists and Engineers (PECASE) in 2019, election to honorary fellowship of the Royal College of Physicians (London), the 2018 Early Career Physician Award from the Virginia Chapter of the American College of Physicians, among others.